Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Climb Bio, Inc., a clinical-stage biotech company, announced it will present new clinical data for its investigational drug budoprutug at the European Hematology Association 2026 Congress. The data includes safety and efficacy results from a Phase 1b/2a trial in patients with primary immune thrombocytopenia, highlighting budoprutug’s potential as a…